Upper Gastrointestinal Safety with the Buffered Solution of Alendronate 70mg: Postmarketing Experience.

被引：0
|
作者：
Hruska, Josef [1 ]
Jorgensen, Flemming Kjaer [2 ]
Eriksen, Erik Fink [3 ]
机构：
[1] MeDACom GmbH, Bern, Switzerland
[2] KLIFO AS, Glostrup, Denmark
[3] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2017年 / 32卷
关键词：
OSTEOPOROSIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SU0292
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
    Hiligsmann, M.
    Maggi, S.
    Veronese, N.
    Sartori, L.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 595 - 606
  • [32] Upper GI tolerability of once-weekly alendronate 70 mg with concomitant NSAID use
    De Papp, AE
    Palmisano, J
    Sackarowitz, JT
    Geba, GP
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S52 - S53
  • [33] Upper GI tolerability of alendronate (FOSAMAX) 70 mg once weekly is similar to placebo.
    Eisman, J
    Rizzoli, R
    Gaines, KA
    Verbruggen, N
    Melton, ME
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S474 - S474
  • [34] Histoacryl injection therapy for the treatment of upper gastrointestinal varices: A North American experience.
    Ormonde, DG
    Ponnudurai, R
    Sandha, GS
    Ter, R
    DuVall, GA
    Cirocco, M
    Bodinaku, K
    Kandel, GP
    Kortan, PP
    Haber, GB
    Marcon, NE
    GASTROINTESTINAL ENDOSCOPY, 2000, 51 (04) : AB122 - AB122
  • [35] COST-EFFECTIVENESS OF BINOSTO (BUFFERED SOLUBLE ALENDRONATE 70 MG) EFFERVESCENT TABLET FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN ITALY
    Hiligsmann, M.
    Maggi, S.
    Veronese, N.
    Sartori, L.
    Reginster, J. Y.
    VALUE IN HEALTH, 2020, 23 : S594 - S594
  • [36] COST-EFFECTIVENESS OF BINOSTO (BUFFERED SOLUBLE ALENDRONATE 70 MG) EFFERVESCENT TABLET FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN ITALY
    Hiligsmann, M.
    Maggi, S.
    Onder, G.
    Galluzzo, L.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S58 - S58
  • [37] Upper GI tolerability of once-weekly alendronate 70 mg with concomitant NSAID use.
    de Papp, AE
    Palmisano, J
    Geba, GP
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S473 - S473
  • [38] Assessment of upper gi tolerability of alendronate (fosamax) 70 mg once weekly vs. placebo
    Eisman, J
    Rizzoli, R
    Gaines, KA
    Verbruggen, N
    Melton, ME
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S42 - S42
  • [39] Oral alendronate 70 mg once weekly is not associated with endoscopic upper GI mucosal lesions compared to placebo.
    Lanza, F
    Sahba, B
    Schwartz, H
    Torosis, J
    Winograd, S
    Quan, H
    Reyes, R
    Leung, A
    Daifotis, A
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S198 - S198
  • [40] Safety And Efficacy of Hemospray® In Upper Gastrointestinal Bleeding: Experience In A Chilean Academic Hospital
    Vivar, Rodrigo Mansilla
    Valenzuela, Carlos
    Gonzalez, Robinson G.
    Parra-Blanco, Adolfo
    Espino, Alberto
    GASTROINTESTINAL ENDOSCOPY, 2016, 83 (05) : AB499 - AB499
12345